Treatment Goals, Side Effects, and Supportive Care Strategies for Patients and Caregivers with HER2+ BC

Opinion
Video

Experts discuss how, discuss patient experiences with an oral chemotherapy regimen, highlighting benefits like treatment autonomy, challenges such as pill burden and gastrointestinal toxicities, and the importance of proactive side effect management and patient education.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What has been your experience with oral regimens and managing toxicities and getting women acclimated to it?

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with brown hair and a floral blouse
      Clinical Trials Can Open Doors for Patients With Myeloproliferative Neoplasms
      Photo of a woman with a blue border around the image
      Nurses, APPs Lead as Sub-Investigators in Oncology Clinical Trials
      2 experts are featured in this series.
      The Impact of Cardiotoxicity Risks in CML: Navigating Dietary Guidelines with TKIs
      2 experts are featured in this series.
      Addressing the Unmet Need in CML Treatment for Patient Treatment Adherence
      Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
      Mobile App Appears Feasible for Cancer Survivor Cognitive Assessment Function
      Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
      Cardiotoxicities in Oncology Necessitate Nurse Vigilance
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Difficulty of Genomic Testing Conversations Highlights Need for Education
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Germline Testing: When to Trust a Patient’s Gut
      2 experts are featured in this series.
      Understanding the Significance of Nilotinib's New Formulation
      Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
      Informing Patients on Integrative Oncology Can Enhance Supportive Care
      Related Content
      Anatomic image of a breast

      T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

      Ashling Wahner
      April 23rd 2025
      Article
      Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

      Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

      Ashley Chan
      March 25th 2025
      Article
      Blue image of a breast with tissue and a tumor highlighted in orange

      KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer

      Ashling Wahner
      February 17th 2025
      Article

      Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

      Simple line illustration of breast tissue on a yellow background

      PFS, Tolerability Increase With Lerociclib/Fulvestrant in HR+/HER– Breast Cancer

      Roman Fabbricatore
      February 10th 2025
      Article

      Lerociclib plus fulvestrant demonstrated a progression-free survival (PFS) advantage across all patient subgroups with HR–positive, HER2–negative advanced breast cancer.

      Simple line illustration on a yellow background of a breast with the tissue illustrated

      T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval

      Chris Ryan
      February 5th 2025
      Article

      The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

      Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard

      Oncology Drugs Approved by the FDA in January 2025

      Darlene Dobkowski, MA
      February 3rd 2025
      Article

      January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.